- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
PKR2 Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP8096a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
PKR2 Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | P13861 |
| Other Accession | KAP2_HUMAN |
| Clone Names | 3011706 |
| Calculated MW | 45518 Da |
PKR2 Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 5576 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP8096a was selected from the N-term region of human PKR2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
PKR2 Antibody (N-term) Blocking Peptide - Protein Information | |
| Name PRKAR2A | |
| Synonyms PKR2, PRKAR2 | |
| Function Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase | |
| Cellular Location Cytoplasm. Cell membrane. Note=Co-localizes with PJA2 in the cytoplasm and the cell membrane | |
| Tissue Location Four types of regulatory chains are found: I- alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible | |
PKR2 Antibody (N-term) Blocking Peptide - Related products
AP6823a: PRKAR2A Antibody (N-term)
AP6823c: PRKAR2A Antibody (Center)
AP8096a: PKA R2 (PKR2) Antibody (N-term)
RI14218: PRKAR2A predesign siRNA
LY10107a: PRKAR2A Over-expression Lysate
BP6823a: PRKAR2A Antibody (N-term) Blocking Peptide
BP6823c: PRKAR2A Antibody (Center) Blocking Peptide
BP8096a: PKR2 Antibody (N-term) Blocking Peptide
AT3430a: PRKAR2A Antibody (monoclonal) (M01)
PKR2 Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase (AMPK), which transduces the signal through phosphorylation of different target proteins. The inactive holoenzyme of AMPK is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits of AMPK have been identified in humans. PKR2 is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. It may interact with various A-kinase anchoring proteins and determine the subcellular localization of AMPK. This subunit has been shown to regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER).
REFERENCES
MacDougall, M.W., et al., J. Clin. Endocrinol. Metab. 88(5):2194-2205 (2003).Birkeli, K.A., et al., J. Biol. Chem. 278(3):1991-1997 (2003).Sun, F., et al., J. Biol. Chem. 275(19):14360-14366 (2000).Zakhary, D.R., et al., J. Biol. Chem. 275(52):41389-41395 (2000).Tasken, K., et al., Genomics 50(3):378-381 (1998).
